Chemoocclusion vs chemoperfusion for treatment of advanced hepatocellular carcinoma: A randomised trial

Abstract

AimsTransarterial chemoembolization (TACE) can be associated with considerable toxicity and treatment-associated mortality. Transient transarterial chemoocclusion (TACO) using degradable starch microspheres (DSM) has been proposed as a potentially safer alternative while maintaining anti-tumour efficiency. In a randomised phase II trial TACO was compared to transarterial chemoperfusion without DSM (TACP). MethodsSeventy-four patients with advanced HCC were randomised to two treatment arms: (i) TACO (600–1200mg DSM) and (ii) TACP. In both arms regional chemotherapy consisted of cisplatin (100mg/m2) and doxorubicin (60mg/m2). Both arms were corresponding in terms of age, gender, liver performance state, and tumour-stage. A maximum of six treatment cycles was applied in monthly intervals. Follow-up was performed in terms of tumour response, time to progression, survival and quality of life. ResultsTumour response rates did not differ significantly between the two treatment arms, however, there was a tendency towards higher response rates in the TACO arm (TACO vs TACP): partial response: 26 vs 9%, stable disease: 41 vs 55%, progressive disease: 33 vs 36%. Time to tumour progression (32 vs 27 weeks), and overall survival (60 vs 69 weeks) were not significantly different. Grade 4 adverse events were rare in both arms and treatment-associated mortality was not observed. In addition, there was no significant difference in terms of quality of life under therapy (EORTC). ConclusionTACO with DSM did not improve response or survival significantly compared to TACP in advanced non-resectable HCC.